BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424 | -11.7% | 16,095 | -42.3% | 0.03% | -15.8% |
| Q2 2023 | $480 | +90.5% | 27,916 | +83.5% | 0.04% | +111.1% |
| Q1 2023 | $252 | -2.3% | 15,216 | -55.0% | 0.02% | -14.3% |
| Q4 2022 | $258 | -99.9% | 33,826 | +1.4% | 0.02% | -32.3% |
| Q3 2022 | $331,000 | -29.9% | 33,350 | -35.8% | 0.03% | -27.9% |
| Q2 2022 | $472,000 | +48.9% | 51,948 | +66.2% | 0.04% | +330.0% |
| Q1 2022 | $317,000 | – | 31,264 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |